REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Clinical trials for REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) trials appear
Sign up with your email to follow new studies for REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo tested for aggressive lymphoma that resists standard treatment
Disease control OngoingThis study is testing whether adding a newer immunotherapy drug called glofitamab to two existing chemotherapy drugs (gemcitabine and oxaliplatin) can help patients with a specific type of aggressive lymphoma that hasn't responded well to initial treatment. The trial will enroll …
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
Higher stem cell dose may boost immune recovery after lymphoma treatment
Disease control OngoingThis study investigates whether giving a higher dose of a patient's own stem cells during transplant leads to better immune system recovery and outcomes for people with aggressive lymphoma that has returned or resisted treatment. Participants with relapsed or refractory diffuse l…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC